Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients

Journal of Clinical Pharmacology

Volumn 53, Issue 3, 2013, Pages 285-293

  Tornatore, Kathleen M ^a,b   Sudchada, Patcharaporn ^a   Attwood, Kris ^a   Wilding, Gregory E ^a   Gundroo, Aijaz C ^b,c   DiFrancesco, Robin ^a   Gray, Vanessa ^c   Venuto, Rocco C ^b,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ERIE COUNTY MEDICAL CENTER   (United States)

Author keywords

Mycophenolic acid; Pharmacokinetics; Race; Renal transplantation

Indexed keywords

ALBUMIN; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AFRICAN AMERICAN; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG CLEARANCE; DRUG FORMULATION; ENTERIC COATED TABLET; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER CIRCULATION; MALE; MAXIMUM PLASMA CONCENTRATION; RACE DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AFRICAN AMERICANS; CHEMISTRY, PHARMACEUTICAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED;

EID: 84877871188     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270012447814     Document Type: Article

References (37)

1. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation . 1996;61:1029-1037.
2. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and glucocorticoid for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet . 1995;345:1321-1325.
3. De Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit . 2009;31(4):416-435.
4. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet . 2007;46:13-58.
5. Budde K, Dürr M, Liefeldt L, Neumayer HH, Glander P. Enteric-coated mycophenolate sodium. Expert Opin Drug Saf . 2010;9(6):981-994.
6. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant . 2007;7(4):888-898.
7. Budde K, Glander P, Krämer BK, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation . 2007;83(4):417-424.
8. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transpl ant. 2004;4(2): 237-243.
9. Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation . 2006;82(11):1413-1418.
10. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant . 2003;3:534-542.
11. Van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant . 2009;9:1495-1499.
12. West-Thielke P, Kaplan B. Therapeutic monitoring of mycophenolic acid: is there clinical utility? Am J Transplant . 2007;7:2441-2442.
13. Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation . 2006;82(8):1004-1012.
14. Meier-Kriesche H, Ojo AO, Leichtman AB, et al. Effect of mycophenolate mofetil on long term outcomes in African American renal transplant recipients. J Am Soc Nephrol . 2000;11:2366-2370.
15. Young CJ, Gaston RS. Medical progress: renal transplantation in black Americans. N Engl J Med . 2000;343:1545-1552.
16. Dirks NL, Huth B, Yates CR, et al. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther . 2004;42:701-718.
17. Neylan J. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation . 1997; 64:1277-1282.
18. Schweitzer E, Yoon S, Fink J, et al. Mycophenolate mofetil reduced the risk of acute rejection less in African-American than Caucasian kidney recipients. Transplantation . 1998;65:242-248.
19. Tornatore KM, Sudchada P, Dole K, et al. Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients. J Clin Pharmacol . 2011;51:1213-1222.
20. Shaw L, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol . 2000;40:624-633.
21. Pescovitz MD, Guasch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant . 2003;3:1581-1586.
22. Food and Drug Administration; Code of Federal Regulations (CFR) Title 21: Food and Drugs; Chapter 1: Food and Drug Administration; Part 320 Bioavailability and Bioequivalence Requirements; http://www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfcfr/CFRsearch. Updated April 1, 2011.
23. Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet . 2006;45:957-964.
24. Huang SM, Temple R. Is the drug or dose for you? impact of ethnic factors in global drug development, regulatory review and clinical practice. Clin Pharmacol Ther . 2008;84:287-294.
25. DiFrancesco R, Frerichs V, Donnelly J, Hagler C, Hochreiter J, Tornatore KM. Simultaneous determination of cortisol, dexamethasone, methylprednisolone, prednisone, prednisolone, mycophenolic acid and mycophenolic acid glucuronide in human plasma utilizing liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci . 2007;859:42-50.
26. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm . 1974; 8:650-655.
27. Sollinger HW, Deierhoi MH, Belzer FO, Deithelm AG, Kaufman RS. RS 61443: a phase I clinical trial and pilot rescue study. Transplantation . 1992;53(2):428-432.
28. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet . 2002;41(10):751-790.
29. Kaplan B, Meier-Kriesche U, Friedman C, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol . 1999;39:715-720.
30. van Hest RM, Mathot RA, Pescovitz MD, Gordon R. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol . 2006;17:871-880.
31. Hoffmann U, Kroemer HK. The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab Rev . 2004;36:669-675.
32. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation . 2006;82:1074-1079.
33. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multi-drug resistance-associated protein 2. Am J Transplant . 2005;5:987-994.
34. Wang, Q, Bhardwaj RK, Herrera-Ruiz D, et al. Expression of multiple drug resistance conferring proteins in normal Chinese and Caucasian small and large intestinal tissue samples. Mol Pharm . 2004;1:447-454.
35. Johnson HJ, Swan SK, Heim-Duthoy KL, et al. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degree of renal function. Clin Pharmacol Ther . 1998;63:512-518.
36. Budde K, Tedesco-Silva H, Pestana JM, et al. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. Ther Drug Monit . 2007;29:381-384.
37. Tedesco-Silva H, Felipe CR, Park SI, et al. Randomized crossover study to assess the inter-and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients. Clin Transplant . 2010;24:E116-E123.